Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVES. Our goals were to (a) describe neonatal behavioral signs in a group of newborns exposed in utero to selective serotonin reuptake inhibitors or venlafaxine at the time of delivery, (b) compare the rate of neonatal behavioral signs, prematurity, and admission to specialized neonatal care between a group of exposed and unexposed newborns, and (c) compare the effects in exposed preterm and term newborns. PATIENTS AND METHODS. This was a retrospective cohort study including mothers taking selective serotonin reuptake inhibitors or venlafaxine during the third trimester and mothers who were not taking any antidepressants, psychotropic agents, or benzodiazepines at the time of delivery of their newborns. Neonatal behavioral signs included central nervous, respiratory, and digestive systems, as well as hypoglycemia and the need for phototherapy. RESULTS. Seventy-six mothers taking antidepressants and 90 untreated mothers and their newborns were analyzed. Smoking, alcohol intake, and substance abuse were more frequent among treated mothers. In infants in the exposed group, signs involving the central nervous and the respiratory systems were often observed (63.2% and 40.8%, respectively). These signs appeared during the first day of life, with a median duration of 3 days for exposed newborns. The signs resolved in 75% of cases within 3 to 5 days for term and premature newborns, respectively. All exposed premature newborns presented behavioral manifestations compared with 69.1% of term exposed newborns. Median length of stay was almost 4 times longer for exposed premature newborns than for those who were unexposed (14.5 vs 3.7 days). CONCLUSIONS. Neonatal behavioral signs were frequently found in exposed newborns, but symptoms were transient and self-limited. Premature infants could be more susceptible to the effects of selective serotonin reuptake inhibitors and venlafaxine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The course of anxiety and depression through pregnancy and the postpartum in a community sample
Heron, J., O'Connor, T. G., Evans, J., Golding, J., & Glover, V. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2003.08.004 · Cited by 1,151
Maternal Depressive Symptoms and the Risk of Poor Pregnancy Outcome
Orr, S. T., & Miller, C. A. (1995) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036172 · Cited by 281
Lattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., & Vazquez, D. M. (2005) · Journal of Perinatology · doi:10.1038/sj.jp.7211352 · Cited by 189
Cited by
Preferences and perceived barriers to treatment for depression during the perinatal period
O'Mahen, H. A., & Flynn, H. A. (2008) · Journal of Women s Health · doi:10.1089/jwh.2007.0631 · Cited by 277
“44 Given emerging conflicting data on the safety of antidepressants during pregnancy 9,10 and the existence of efficacious psy-chotherapies, however, it is also important to improve pregnant women’s awareness of and access to psychotherapy as a treatment option.”
Ross, L. E., Grigoriadis, S., Mamisashvili, L., VonderPorten, E. H., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.684 · Cited by 268
Antidepressant use in pregnancy: a critical review focused on risks and controversies
Byatt, N., Deligiannidis, K. M., & Freeman, M. P. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12042 · Cited by 158
“…nortriptyline 21 mother–infant pairs with antidepressant exposure No association between cord-to-maternal concentration ratios and perinatal events Ferreira et al. (2007) (117) Retrospective chart review Fluoxetine, citalopram, paroxetine, sertraline 66 neonates with SSRI exposure vs. 90…”
BackgroundVigod, S. N., Wilson, C. A., & Howard, L. M. (2016) · BMJ · doi:10.1136/bmj.i1547 · Cited by 148
Antidepressants in pregnancy: a systematic review.
(2010) · PubMed · doi:10.3109/00048674.2010.507543 · Cited by 128
Calderon-Margalit, R., Qiu, C., Ornoy, A., Siscovick, D. S., & Williams, M. A. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.06.061 · Cited by 115
The use of psychotropic medication during pregnancy: how about the newborn?
Kieviet, N., Honig, & Dolman (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36394 · Cited by 100
Tuccori, M., Testi, A., Antonioli, L., Fornai, M., Montagnani, S., Ghisu, N., Colucci, R., Corona, T., Blandizzi, C., & Tacca, M. D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.07.009 · Cited by 95
Convertino, I., Sansone, A. C., Marino, A., Galiulo, M. T., Mantarro, S., Antonioli, L., Fornai, M., Blandizzi, C., & Tuccori, M. (2016) · Drug Safety · doi:10.1007/s40264-016-0435-8 · Cited by 32
Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20166565 · Cited by 17
Metadata
- Authors
- Ferreira, E., Carceller, A. M., Agogué, C., Martin, B. Z., St-André, M., Francoeur, D., & Bérard, A.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2007-01-01
- Volume
- 119
- Issue
- 1
- Pages
- 52-59
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2015498942
- Cited by
- 135
- References
- 3
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.